Feed / CAPR

Capricor Therapeutics, Inc.

CAPR

Healthcare · 7.99 -61.3% today

Dominant mover · weak group confirmationMarket checked 19 Aug, 15:55 GMT-4

Jodie situation report

CAPR dominates a concentrated Clinical-Stage Biotech move.

CAPR accounts for 53.6% of the group's measured movement across 2.0 effective names. raw member direction is mixed; 1 of 2 session-normalized paths align to the upside. Capital-flow agreement is 38%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveDominant mover#1 of 2 by movement share
Group movement share53.6%Absolute path energy—not portfolio weight
Relative path+5.48%aligned
Effective breadth2.0 / 2concentrated
Relative alignment1/2upside path · 1 counter-moving
Capital-flow agreement38%not yet clean
SEQUENCE READ

CAPR was the first measured mover. CAPR crossed its material path threshold at 10:00 ET. STRO followed.

EVIDENCE COVERAGE

2 of 2 members in Clinical-Stage Biotech are active. 1 of 6 disclosed connections are confirming.

What would change this read
  • At least 2 of 2 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • EWTX remains aligned with the group in the next market snapshot.

Invalidation: The live read weakens if participation falls to 1 of 2 members or fewer.

Watch this read

Who this business touches

The relationships behind CAPR

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

TMOThermo Fisher Scientific IncsupplierMar 17, 2026

13 Table of Contents Cell Line License Agreement with Life Technologies On March 7, 2022, Capricor entered into a non-exclusive cell line license agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, Inc., for the supply of c…

OPYOppenheimer Holdings, Inc.partnerNov 10, 2025

g under a prospectus supplement for aggregate sales proceeds of up to $150.0 million (the “September 2025 ATM Program”) on September 10, 2025, pursuant to an Equity Distribution Agreement with Piper Sandler and Oppenheimer (collectively, the “Agents”) by whic…

Depended on by

BCDABioCardia, Inc.competitorMar 24, 2026

The industry continues to expand and evolve as an increasing number of competitors and potential competitors enter the market, including AstraZeneca, Bayer, Blue Rock Therapeutics, Bristol-Myers Squibb, Lisata Therapeutics, Capricor Therapeutics, Celixir, Cel…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

CAPR is currently a Early Follower in the organic co-movement group Clinical-Stage Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.